E 1 (open stabilization): With the 15 subjects with cannabis use problems, 53 no longer met the criteria for active cannabis abuse or had entered into early full remission. With the 9 subjects with cocaine use problems, 78 no longer met the criteria for active cocaine abuse or had entered into early full remission. In comparison with baseline, a important in mood symptoms was Charybdotoxin Protocol observed for both interventions. Phase two (DB RCT): No differences in mood outcomes between interventions.Prisciandaro et al., 2021 [43]CannabisGabapentinGao et al., 2017 [44] CannabisCannabis, Alcohol or bothQuetiapine XRKemp et al., 2009 [45]Alcohol, cannabis, cocaineLithium vs. lithium valproateRapid cycling BD I or II Phase 1: N = 149; Phase two: N =6 months open label stabilization followed by 6 months DB RCT.Geller et al., 1998 [46]Alcohol, Cannabis, InhalantsLithiumAdolescents with BD I or II, single manic episode, or MDD with at least a single predictor of future BD. N = 25, 2 on cannabis only and 14 on cannabis alcohol6 weeks DB, PLC controlled RCT add on to TAUThe lithium group showed considerable across mood and substance use outcome measures, in comparison to placebo. Tiny sample size, no separate outcome information reported for cannabis.Medicina 2021, 57,8 ofTable two. Cont.Substance Study Substances Intervention Bipolar Diagnosis and N Style 20 weeks DB, add on to anticonvulsants or antidepressants. No PLC handle six months open label stabilization followed by 6 months DB RCT. ten weeks DB, PLC controlled add-on to TAU 12 weeks DB, PLC controlled add-on to TAU 12 weeks DB, PLC controlled add-on to TAU Outcome/Limitations Both study drugs have been associated having a considerable in manic, depressive, or mixed mood states compared to baseline scores. Each medications had been also related with drug cravings and use. Restricted proof within the absence of a PLC control. No separate results were reported for cocaine. See heading “Cannabis”. Phase 1 (open stabilization): Of 9 subjects with cocaine use disorders, 78 no longer met criteria for active cocaine abuse or had entered into early complete remission. No variations in mood outcomes and craving involving lamotrigine and placebo. The lamotrigine group showed a higher in quantity spent on cocaine. There had been no substantial adjustments in psychiatric symptoms in between groups. A substantial within the variety of cocaine-positive urine screens was observed. Citicoline active cocaine use plus the likelihood of relapse. There was no important distinction in craving symptoms in between groups. No considerable modifications in mood symptoms.Nejtek et al., 2008 [41]Cocaine or methamphetamineQuetiapine or RisperidoneBD I or II. N =Kemp et al., 2009 [45] Cocaine Brown et al., 2012 [47] Brown et al., 2007 [48] Brown et al., 2015 [49]Alcohol, cannabis, cocaineLithium vs. lithium valproateRapid cycling Bipolar I or II disorder. Phase 1: N = 149; Phase 2: N = 31 BD I, II, BD-NOS and cyclothymia, Oligomycin custom synthesis depressed or mixed, N = 120 BD I or II (history of at the least a single (hypo)manic episode. N = 44 BD I (depressed or mixed mood state) N =CocaineLamotrigineCocaine and at least on other SUDCiticolineCocaineCiticolineBD I: Bipolar I disorder; BD II: Bipolar II disorder; BD NOS: Bipolar disorder not otherwise specified; dACC: dorsal anterior cingulate cortex; DB: Double-blind; GBP: Gabapentin; IDS: Inventory of depressive symptoms; MDD: Big depressive disorder; PLC: Placebo; pMCC: posterior midcingulate cortex; rBG: suitable basal ganglia; RCT: Randomized controlled trial; TAU Treatment as.